Continuation Pharmacotherapy in the Prevention of Relapse Following Electroconvulsive Therapy

Authors:
  • RHRoger F. Haskett
    Roger F. Haskett
  • BMBenoit H. Mulsant
    Benoit H. Mulsant
  • MTMichael E. Thase
    Michael E. Thase
  • JMJ. John Mann
    J. John Mann
  • HPHelen M. Pettinati
    Helen M. Pettinati
  • RGRobert M. Greenberg
    Robert M. Greenberg
  • RCRaymond R. Crowe
    Raymond R. Crowe
  • TCThomas B. Cooper
    Thomas B. Cooper
  • JPJoan Prudic
    Joan Prudic
Top Cited Papers
Publisher website
Google Scholar
Abstract
Research from JAMA — Continuation Pharmacotherapy in the Prevention of Relapse Following Electroconvulsive Therapy — A Randomized Controlled Trial — ContextElectroconvulsive therapy (ECT) is highly effective for treatment of major depression, but naturalistic studies show a high rate of relapse after discontinuation of ECT.ObjectiveTo determine the efficacy of continuation pharmacotherapy with nortriptyline hydrochloride or combination nortriptyline and lithium carbonate in preventing post-ECT relapse.DesignRandomized, double-blind, placebo-controlled trial conducted from 1993 to 1998, stratified by medication resistance or presence of psychotic depression in the index episode.SettingTwo university-based hospitals and 1 private psychiatric hospital.PatientsOf 290 patients with unipolar major depression recruited through clinical referral who completed an open ECT treatment phase, 159 patients met remitter criteria; 84 remitting patients were eligible and agreed to participate in the continuation study.InterventionsPatients were randomly assigned to receive continuation treatment for 24 weeks with placebo (n = 29), nortriptyline (target steady-state level, 75-125 ng/mL) (n = 27), or combination nortriptyline and lithium (target steady-state level, 0.5-0.9 mEq/L) (n = 28).Main Outcome MeasureRelapse of major depressive episode, compared among the 3 continuation groups.ResultsNortriptyline-lithium combination therapy had a marked advantage in time to relapse, superior to both placebo and nortriptyline alone. Over the 24-week trial, the relapse rate for placebo was 84% (95% confidence interval [CI], 70%-99%); for nortriptyline, 60% (95% CI, 41%-79%); and for nortriptyline-lithium, 39% (95% CI, 19%-59%). All but 1 instance of relapse with nortriptyline-lithium occurred within 5 weeks of ECT termination, while relapse continued throughout treatment with placebo or nortriptyline alone. Medication-resistant patients, female patients, and those with more severe depressive symptoms following ECT had more rapid relapse.ConclusionsOur study indicates that without active treatment, virtually all remitted patients relapse within 6 months of stopping ECT. Monotherapy with nortriptyline has limited efficacy. The combination of nortriptyline and lithium is more effective, but the relapse rate is still high, particularly during the first month of continuation therapy.

This publication has 35 references indexed in Scilit: